NSE/Alb as a Prognostic Biomarker for Lung Cancer
NCT03724604 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 202
Last updated 2019-05-21
Summary
The incidence and mortality rate of lung cancer is the highest in the world. Current studies have found that tumor markers, inflammatory or nutritional indicators have a good predictive value for the prognosis of patients with non-small cell lung cancer (NSCLC). Neuron specific enolase (NSE) and serum albumin (Alb) are important indicators for monitoring tumor progression and nutritional status in lung cancer patients, respectively. Previous studies suggested that the higher the NSE, the worse prognosis of NSCLC patients, while the lower the Alb, the worse the prognosis of patients with malignant tumors. Through a retrospective study, the investigators found that NAR (NSE Alb Ratio) was higher and prognosis was poorer in patients undergoing NSCLC surgery. This is better than the previous assessment indicators PLR (platelet to lymphocyte ratio), NLR (neutrophil to lymphocyte ratio), AGR (albumin to globulin ratio), NAR can better assess prognosis. Therefore, on the basis of the previous retrospective analysis, the optimal NAR cut-off value was calculated according to ROC curve, and the value was grouped into multi-center prospective cohort study, and the relationship between NAR and other clinical indicators was studied by chi-square test. Univariate and multivariate analysis of Cox proportional hazard regression model was used to determine the prognostic factors. Finally, NSCLC patients were stratified according to tumor stage and pathological classification, and the differences of survival time between high NAR group and low NAR group were compared again under different stages and types, and the different stages of NAR in NSCLC patients were further analyzed. The clinical significance of typing. By exploring and validating the relationship between NAR and the prognosis of NSCLC patients, the investigators try to establish a new prognostic index. Obviously, it has important value for clinical application.
Conditions
- Carcinoma, Non-Small-Cell Lung
Interventions
- DIAGNOSTIC_TEST
-
Neuron-Specific Enolase to Albumin Ratio
Previous studies have shown that inflammation and nutrition-related factors such as CRP/Alb (C-reactive protein-albumin ratio), PLR (platelet-to-lymphocyte ratio), NLR (neutrophil-to-lymphocyte ratio) can help to assess the prognosis of malignant tumors. This study is the first time to combine NSCLC tumor marker NSE and patient nutrition-related indicators Alb to predict the prognosis of patients, trying to find high sensitivity and specificity for NSCLC prognostic indicators to guide clinical work.
Sponsors & Collaborators
-
Second Affiliated Hospital of Xi'an Jiaotong University
collaborator OTHER -
Shaanxi Provincial Cancer Hospital
collaborator OTHER -
Shaanxi Provincial People's Hospital
collaborator OTHER -
Xi'an Central Hospital
collaborator OTHER -
First Affiliated Hospital Xi'an Jiaotong University
lead OTHER
Principal Investigators
-
Sida Qin, MD PhD · First Affiliated Hospital Xi'an Jiaotong University
Eligibility
- Min Age
- 18 Years
- Max Age
- 70 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2017-01-01
- Primary Completion
- 2019-06-30
- Completion
- 2019-06-30
Countries
- China
Study Locations
More Related Trials
-
Role of Serum Albumin and Total Protein in Survival of Cancer Cachectic Patients
NCT05103059 ·Status: UNKNOWN
-
Serum Exosomal Long Noncoding RNAs as Potential Biomarkers for Lung Cancer Diagnosis
NCT03830619 ·Status: COMPLETED
-
Prognostic Value of Sarcopenia and Nutritional Status in Early-stage Non-small Cell Lung Cancer
NCT05212285 ·Status: COMPLETED
-
Pleural Effusion Biomarkers in Lung Adenocarcinoma Patients
NCT07012759 ·Status: RECRUITING
-
ctDNA Dynamic Monitoring and Its Role of Prognosis in Stage I NSCLS by NGS
NCT03172156 ·Status: COMPLETED
-
ctDNA Dynamic Monitoring and Its Role of Prognosis in Stage II to IIIA NSCLC by NGS
NCT03465241 ·Status: COMPLETED
-
Multicenter Observational Study of Advanced Non-small Cell Lung Cancer With Malignant Pleural Effusion
NCT04263688 ·Status: UNKNOWN
-
The Accuracy of Targeted Lymph Node Dissection of Non-small Cell Lung Cancer Patients According to Predictive Models
NCT06768853 ·Status: NOT_YET_RECRUITING ·Phase: NA
-
Association Between VEGF-C and miRNA and Clinical Non-small Cell Lung Cancer and Esophagus Squamous Cell Carcinoma
NCT01240369 ·Status: UNKNOWN
-
Biomarkers of Stage III Locally Advanced Unresectable Non-small-cell Lung Cancer
NCT04749407 ·Status: UNKNOWN
-
A Prospective Cohort Study of Chinese Patients With Pulmonary Nodules: Prediction of Lung Cancer Using Noninvasive Biomarkers
NCT04462185 ·Status: UNKNOWN
-
Evaluate the Utility of the ProLung China Test in the Diagnosis of Lung Cancer
NCT02726633 ·Status: UNKNOWN
-
Predictive Value of Exosomes in Pleural Effusion for Advanced Lung Cancer
NCT07262671 ·Status: ACTIVE_NOT_RECRUITING
-
A Study of Real-world Treatment Patterns and Outcomes in Chinese Advanced NSCLC Patients Who Previously Received at Least 2 Line Treatments
NCT06617390 ·Status: COMPLETED
-
Differences in Rate of Decline in CT-defined Skeletal Muscle Mass and Physical Performance in Patients With Advanced Non-small Cell Lung Cancer Receiving Chemotherapy and Targeted Therapy/Immunotherapy, Before and After Treatment.
NCT06326086 ·Status: RECRUITING
-
Plasma Proteomic Biomarkers for Early Diagnosis of Lung Cancer
NCT05742204 ·Status: ACTIVE_NOT_RECRUITING
-
Adjuvant Chemotherapy for High-Risk Pathologic Stage I Non-Squamous NSCLC
NCT07250360 ·Status: COMPLETED
-
Artificial Intelligence-based Model for the Prediction of Occult Lymph Node Metastasis and Improvement of Clinical Decision-making in Non-small Cell Lung Cancer
NCT06684418 ·Status: RECRUITING
-
Precision Diagnosis for Intraoperative Frozen Section of Early Stage Lung Cancer
NCT02941003 ·Status: UNKNOWN ·Phase: NA
-
Assessment of Early-detection Based on Liquid Biopsy in Lung Cancer (ASCEND-LUNG)
NCT04817046 ·Status: UNKNOWN
-
Survival Analysis and Prognostic Biomarker Exploration of Postoperative Adjuvant Therapy Patterns in Patients With Non-small Cell Lung Cancer After Neoadjuvant Immunotherapy
NCT07256002 ·Status: ACTIVE_NOT_RECRUITING
-
Development and Application of Molecular Evaluation Instrument for Lung Cancer Diagnosis and Treatment
NCT06086587 ·Status: NOT_YET_RECRUITING
-
Prognostic Factors on Malignant Pleural Effusion
NCT03276715 ·Status: COMPLETED
-
To Evaluate the Correlation Between the Results of Specific Gene Testing and the Efficacy of Targeted Therapy in Patients With NSCLC
NCT05805267 ·Status: COMPLETED
-
A Multi-centre Chart Review Study of Stage I-III Non-Small Cell Lung Cancer in China
NCT07316062 ·Status: RECRUITING